ID   KPB2_HUMAN              Reviewed;        1235 AA.
AC   P46019; A8K1T1; Q6LAJ5; Q7Z6W0; Q96CR3; Q9UDA1;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   10-MAY-2017, entry version 175.
DE   RecName: Full=Phosphorylase b kinase regulatory subunit alpha, liver isoform;
DE            Short=Phosphorylase kinase alpha L subunit;
GN   Name=PHKA2; Synonyms=PHKLA, PYK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS GSD9A PHE-141 DEL AND
RP   LEU-1205.
RC   TISSUE=Liver;
RX   PubMed=7847371;
RA   van den Berg I.E.T., van Beurden E.A.C.M., Malingre H.E.M.,
RA   Ploos van Amstel H.K., Poll-The B.T., Smeitink J.A.M., Lamers W.H.,
RA   Berger R.;
RT   "X-linked liver phosphorylase kinase deficiency is associated with
RT   mutations in the human liver phosphorylase kinase alpha subunit.";
RL   Am. J. Hum. Genet. 56:381-387(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GSD9A VAL-193.
RC   TISSUE=Liver;
RX   PubMed=7549948;
RA   Hirono H., Hayasaka K., Sato W., Takahashi T., Takada G.;
RT   "Isolation of cDNA encoding the human liver phosphorylase kinase alpha
RT   subunit (PHKA2) and identification of a missense mutation of the PHKA2
RT   gene in a family with liver phosphorylase kinase deficiency.";
RL   Biochem. Mol. Biol. Int. 36:505-511(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GSD9A CYS-186;
RP   HIS-186; 189-LYS-THR-190 DEL; HIS-295 AND LYS-1125.
RC   TISSUE=Liver;
RX   PubMed=10330341; DOI=10.1086/302399;
RA   Hendrickx J., Lee P., Keating J.P., Carton D., Sardharwalla I.B.,
RA   Tuchman M., Baussan C., Willems P.J.;
RT   "Complete genomic structure and mutational spectrum of PHKA2 in
RT   patients with X-linked liver glycogenosis type I and II.";
RL   Am. J. Hum. Genet. 64:1541-1549(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 178-206, AND VARIANTS GSD9A
RP   GLU-189; SER-399; 818-GLN--TYR-825 DEL; 953-ASN--LEU-954 DELINS ILE
RP   AND TRP-1207.
RX   PubMed=9600238; DOI=10.1007/s004390050715;
RA   Burwinkel B., Amat L., Gray R.G., Matsuo N., Muroya K., Narisawa K.,
RA   Sokol R.J., Vilaseca M.A., Kilimann M.W.;
RT   "Variability of biochemical and clinical phenotype in X-linked liver
RT   glycogenosis with mutations in the phosphorylase kinase PHKA2 gene.";
RL   Hum. Genet. 102:423-429(1998).
RN   [9]
RP   NUCLEOTIDE SEQUENCE OF 750-1126.
RC   TISSUE=Liver;
RX   PubMed=8518797; DOI=10.1093/hmg/2.5.583;
RA   Hendrickx J., Coucke P., Bossuyt P., Wauters J., Raeymaekers P.,
RA   Marchau F., Smit G.P., Stolte I., Sardharwalla I.B., Berthelot J.;
RT   "X-linked liver glycogenosis: localization and isolation of a
RT   candidate gene.";
RL   Hum. Mol. Genet. 2:583-589(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 977-1080.
RC   TISSUE=Liver;
RX   PubMed=8226841;
RA   Wuellrich A., Hamacher C., Schneider A., Kilimann M.W.;
RT   "The multiphosphorylation domain of the phosphorylase kinase alpha M
RT   and alpha L subunits is a hotspot of differential mRNA processing and
RT   of molecular evolution.";
RL   J. Biol. Chem. 268:23208-23214(1993).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729; SER-735 AND
RP   SER-1015, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1015, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729 AND SER-1015, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729 AND SER-735, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-695; SER-729; SER-735
RP   AND SER-1015, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729; SER-983 AND
RP   SER-1044, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   VARIANTS GSD9A CYS-186; THR-251 DEL; THR-ARG-1111 INS AND ILE-1114.
RX   PubMed=8733133; DOI=10.1093/hmg/5.5.649;
RA   Hendrickx J., Dams E., Coucke P., Lee P., Fernandes J., Willems P.J.;
RT   "X-linked liver glycogenosis type II (XLG II) is caused by mutations
RT   in PHKA2, the gene encoding the liver alpha subunit of phosphorylase
RT   kinase.";
RL   Hum. Mol. Genet. 5:649-652(1996).
RN   [20]
RP   VARIANTS GSD9A PRO-132; TYR-132; HIS-186 AND GLY-299.
RX   PubMed=8733134; DOI=10.1093/hmg/5.5.653;
RA   Burwinkel B., Shin Y.S., Bakker H.D., Deutsch J., Lozano M.J.,
RA   Maire I., Kilimann M.W.;
RT   "Mutation hotspots in the PHKA2 gene in X-linked liver glycogenosis
RT   due to phosphorylase kinase deficiency with atypical activity in blood
RT   cells (XLG2).";
RL   Hum. Mol. Genet. 5:653-658(1996).
RN   [21]
RP   VARIANTS GSD9A TYR-ASN-THR-ALA-THR-120 INS; GLY-299; LEU-498; ARG-869;
RP   TRP-916; ARG-1070 DEL AND ILE-1113.
RX   PubMed=17689125; DOI=10.1016/j.ymgme.2007.06.007;
RA   Beauchamp N.J., Dalton A., Ramaswami U., Niinikoski H., Mention K.,
RA   Kenny P., Kolho K.L., Raiman J., Walter J., Treacy E., Tanner S.,
RA   Sharrard M.;
RT   "Glycogen storage disease type IX: High variability in clinical
RT   phenotype.";
RL   Mol. Genet. Metab. 92:88-99(2007).
CC   -!- FUNCTION: Phosphorylase b kinase catalyzes the phosphorylation of
CC       serine in certain substrates, including troponin I. The alpha
CC       chain may bind calmodulin.
CC   -!- ENZYME REGULATION: By phosphorylation of various serine residues
CC       and by calcium.
CC   -!- PATHWAY: Glycan biosynthesis; glycogen metabolism.
CC   -!- SUBUNIT: Hexadecamer of 4 heterotetramers, each composed of alpha,
CC       beta, gamma, and delta subunits. Alpha (PHKA1 or PHKA2) and beta
CC       (PHKB) are regulatory subunits, gamma (PHKG1 or PHKG2) is the
CC       catalytic subunit, and delta is calmodulin.
CC   -!- INTERACTION:
CC       P15735:PHKG2; NbExp=4; IntAct=EBI-1642846, EBI-1383819;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Lipid-anchor
CC       {ECO:0000305}; Cytoplasmic side {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in liver and other
CC       non-muscle tissues.
CC   -!- PTM: Although the final Cys may be farnesylated, the terminal
CC       tripeptide is probably not removed, and the C-terminus is not
CC       methylated. {ECO:0000250|UniProtKB:P18688}.
CC   -!- DISEASE: Glycogen storage disease 9A (GSD9A) [MIM:306000]: A
CC       metabolic disorder resulting in a mild liver glycogenosis with
CC       clinical symptoms that include hepatomegaly, growth retardation,
CC       muscle weakness, elevation of glutamate-pyruvate transaminase and
CC       glutamate-oxaloacetate transaminase, hypercholesterolemia,
CC       hypertriglyceridemia, and fasting hyperketosis. Two subtypes are
CC       known: type 1 or classic type with no phosphorylase kinase
CC       activity in liver or erythrocytes, and type 2 or variant type with
CC       no phosphorylase kinase activity in liver, but normal activity in
CC       erythrocytes. Unlike other glycogenosis diseases, glycogen storage
CC       disease type 9A is generally a benign condition. Patients improve
CC       with age and are often asymptomatic as adults. Accurate diagnosis
CC       is therefore also of prognostic interest.
CC       {ECO:0000269|PubMed:10330341, ECO:0000269|PubMed:17689125,
CC       ECO:0000269|PubMed:7549948, ECO:0000269|PubMed:7847371,
CC       ECO:0000269|PubMed:8733133, ECO:0000269|PubMed:8733134,
CC       ECO:0000269|PubMed:9600238}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the phosphorylase b kinase regulatory chain
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X80497; CAA56662.1; -; mRNA.
DR   EMBL; D38616; BAA07606.1; -; mRNA.
DR   EMBL; AF044572; AAD32846.1; -; Genomic_DNA.
DR   EMBL; AF044540; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044541; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044542; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044543; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044544; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044545; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044546; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044547; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044548; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044549; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044550; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044551; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044552; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044553; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044554; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044555; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044556; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044557; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044558; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044559; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044560; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044561; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044562; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044563; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044564; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044565; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044566; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044567; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044568; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044569; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044570; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AF044571; AAD32846.1; JOINED; Genomic_DNA.
DR   EMBL; AK289996; BAF82685.1; -; mRNA.
DR   EMBL; AL096700; CAB86408.2; -; Genomic_DNA.
DR   EMBL; AL732509; CAB86408.2; JOINED; Genomic_DNA.
DR   EMBL; AL732509; CAI41680.1; -; Genomic_DNA.
DR   EMBL; AL096700; CAI41680.1; JOINED; Genomic_DNA.
DR   EMBL; CH471074; EAW98951.1; -; Genomic_DNA.
DR   EMBL; BC014036; AAH14036.1; -; mRNA.
DR   EMBL; Y15154; CAA75421.1; -; Genomic_DNA.
DR   EMBL; X73875; CAA52084.1; -; mRNA.
DR   CCDS; CCDS14190.1; -.
DR   RefSeq; NP_000283.1; NM_000292.2.
DR   UniGene; Hs.54941; -.
DR   ProteinModelPortal; P46019; -.
DR   BioGrid; 111274; 24.
DR   IntAct; P46019; 13.
DR   MINT; MINT-1185164; -.
DR   STRING; 9606.ENSP00000369274; -.
DR   ChEMBL; CHEMBL2111324; -.
DR   iPTMnet; P46019; -.
DR   PhosphoSitePlus; P46019; -.
DR   BioMuta; PHKA2; -.
DR   DMDM; 1170685; -.
DR   EPD; P46019; -.
DR   MaxQB; P46019; -.
DR   PaxDb; P46019; -.
DR   PeptideAtlas; P46019; -.
DR   PRIDE; P46019; -.
DR   DNASU; 5256; -.
DR   Ensembl; ENST00000379942; ENSP00000369274; ENSG00000044446.
DR   GeneID; 5256; -.
DR   KEGG; hsa:5256; -.
DR   UCSC; uc004cyv.5; human.
DR   CTD; 5256; -.
DR   DisGeNET; 5256; -.
DR   GeneCards; PHKA2; -.
DR   GeneReviews; PHKA2; -.
DR   H-InvDB; HIX0176778; -.
DR   HGNC; HGNC:8926; PHKA2.
DR   HPA; HPA002912; -.
DR   MalaCards; PHKA2; -.
DR   MIM; 300798; gene.
DR   MIM; 306000; phenotype.
DR   neXtProt; NX_P46019; -.
DR   OpenTargets; ENSG00000044446; -.
DR   Orphanet; 264580; Glycogen storage disease due to liver phosphorylase kinase deficiency.
DR   PharmGKB; PA33267; -.
DR   eggNOG; KOG3635; Eukaryota.
DR   eggNOG; ENOG410XPJZ; LUCA.
DR   GeneTree; ENSGT00520000055553; -.
DR   HOGENOM; HOG000231478; -.
DR   HOVERGEN; HBG000273; -.
DR   InParanoid; P46019; -.
DR   KO; K07190; -.
DR   OMA; YCYLILF; -.
DR   OrthoDB; EOG091G00NN; -.
DR   PhylomeDB; P46019; -.
DR   TreeFam; TF313970; -.
DR   BioCyc; MetaCyc:HS00576-MONOMER; -.
DR   BRENDA; 2.7.11.19; 2681.
DR   Reactome; R-HSA-70221; Glycogen breakdown (glycogenolysis).
DR   UniPathway; UPA00163; -.
DR   GeneWiki; PHKA2; -.
DR   GenomeRNAi; 5256; -.
DR   PRO; PR:P46019; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000044446; -.
DR   CleanEx; HS_PHKA2; -.
DR   Genevisible; P46019; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005964; C:phosphorylase kinase complex; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0004689; F:phosphorylase kinase activity; TAS:ProtInc.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:ProtInc.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0005980; P:glycogen catabolic process; TAS:Reactome.
DR   InterPro; IPR008928; 6-hairpin_glycosidase-like.
DR   InterPro; IPR011613; Glyco_hydro_15/PHK.
DR   InterPro; IPR008734; PHK_A/B_su.
DR   PANTHER; PTHR10749; PTHR10749; 1.
DR   Pfam; PF00723; Glyco_hydro_15; 1.
DR   SUPFAM; SSF48208; SSF48208; 1.
PE   1: Evidence at protein level;
KW   Calmodulin-binding; Carbohydrate metabolism; Cell membrane;
KW   Complete proteome; Disease mutation; Glycogen metabolism;
KW   Glycogen storage disease; Lipoprotein; Membrane; Phosphoprotein;
KW   Polymorphism; Prenylation; Reference proteome.
FT   CHAIN         1   1235       Phosphorylase b kinase regulatory subunit
FT                                alpha, liver isoform.
FT                                /FTId=PRO_0000057730.
FT   REGION      807    837       Calmodulin-binding. {ECO:0000255}.
FT   REGION     1059   1099       Calmodulin-binding. {ECO:0000255}.
FT   MOD_RES     695    695       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     729    729       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     735    735       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     983    983       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1015   1015       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1044   1044       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   LIPID      1232   1232       S-farnesyl cysteine.
FT                                {ECO:0000250|UniProtKB:P18688}.
FT   VARIANT      38     38       E -> Q (in dbSNP:rs17313469).
FT                                /FTId=VAR_024563.
FT   VARIANT     120    120       T -> TYNTAT (in GSD9A).
FT                                /FTId=VAR_062393.
FT   VARIANT     132    132       H -> P (in GSD9A; type 2;
FT                                dbSNP:rs137852291).
FT                                {ECO:0000269|PubMed:8733134}.
FT                                /FTId=VAR_006177.
FT   VARIANT     132    132       H -> Y (in GSD9A; type 2;
FT                                dbSNP:rs137852292).
FT                                {ECO:0000269|PubMed:8733134}.
FT                                /FTId=VAR_006178.
FT   VARIANT     141    141       Missing (in GSD9A; type 1).
FT                                {ECO:0000269|PubMed:7847371}.
FT                                /FTId=VAR_006179.
FT   VARIANT     186    186       R -> C (in GSD9A; type 2;
FT                                dbSNP:rs137852294).
FT                                {ECO:0000269|PubMed:10330341,
FT                                ECO:0000269|PubMed:8733133}.
FT                                /FTId=VAR_006180.
FT   VARIANT     186    186       R -> H (in GSD9A; type 2;
FT                                dbSNP:rs137852290).
FT                                {ECO:0000269|PubMed:10330341,
FT                                ECO:0000269|PubMed:8733134}.
FT                                /FTId=VAR_006181.
FT   VARIANT     189    190       Missing (in GSD9A; type 2).
FT                                {ECO:0000269|PubMed:10330341}.
FT                                /FTId=VAR_012270.
FT   VARIANT     189    189       K -> E (in GSD9A; type 2;
FT                                dbSNP:rs137852295).
FT                                {ECO:0000269|PubMed:9600238}.
FT                                /FTId=VAR_012269.
FT   VARIANT     193    193       G -> V (in GSD9A; type 2).
FT                                {ECO:0000269|PubMed:7549948}.
FT                                /FTId=VAR_012271.
FT   VARIANT     251    251       Missing (in GSD9A; type 2).
FT                                {ECO:0000269|PubMed:8733133}.
FT                                /FTId=VAR_006182.
FT   VARIANT     295    295       R -> H (in GSD9A; type 1 and type 2;
FT                                dbSNP:rs797044877).
FT                                {ECO:0000269|PubMed:10330341}.
FT                                /FTId=VAR_012272.
FT   VARIANT     299    299       D -> G (in GSD9A; type 2;
FT                                dbSNP:rs137852289).
FT                                {ECO:0000269|PubMed:17689125,
FT                                ECO:0000269|PubMed:8733134}.
FT                                /FTId=VAR_006183.
FT   VARIANT     399    399       P -> S (in GSD9A; type 1).
FT                                {ECO:0000269|PubMed:9600238}.
FT                                /FTId=VAR_012273.
FT   VARIANT     416    416       G -> R (in dbSNP:rs16980929).
FT                                /FTId=VAR_050518.
FT   VARIANT     498    498       P -> L (in GSD9A; dbSNP:rs199792389).
FT                                {ECO:0000269|PubMed:17689125}.
FT                                /FTId=VAR_062394.
FT   VARIANT     818    825       Missing (in GSD9A; type 1).
FT                                {ECO:0000269|PubMed:9600238}.
FT                                /FTId=VAR_012274.
FT   VARIANT     869    869       P -> R (in GSD9A; dbSNP:rs777137574).
FT                                {ECO:0000269|PubMed:17689125}.
FT                                /FTId=VAR_062395.
FT   VARIANT     916    916       R -> W (in GSD9A).
FT                                {ECO:0000269|PubMed:17689125}.
FT                                /FTId=VAR_062396.
FT   VARIANT     953    954       NL -> I (in GSD9A; type 1).
FT                                /FTId=VAR_012275.
FT   VARIANT    1070   1070       Missing (in GSD9A).
FT                                {ECO:0000269|PubMed:17689125}.
FT                                /FTId=VAR_062397.
FT   VARIANT    1111   1111       R -> RTR (in GSD9A; type 2).
FT                                /FTId=VAR_006184.
FT   VARIANT    1113   1113       M -> I (in GSD9A).
FT                                {ECO:0000269|PubMed:17689125}.
FT                                /FTId=VAR_062398.
FT   VARIANT    1114   1114       T -> I (in GSD9A; type 2;
FT                                dbSNP:rs137852293).
FT                                {ECO:0000269|PubMed:8733133}.
FT                                /FTId=VAR_006185.
FT   VARIANT    1125   1125       E -> K (in GSD9A; type 1).
FT                                {ECO:0000269|PubMed:10330341}.
FT                                /FTId=VAR_012276.
FT   VARIANT    1205   1205       P -> L (in GSD9A; type 1;
FT                                dbSNP:rs137852288).
FT                                {ECO:0000269|PubMed:7847371}.
FT                                /FTId=VAR_006186.
FT   VARIANT    1207   1207       G -> W (in GSD9A; type 1).
FT                                {ECO:0000269|PubMed:9600238}.
FT                                /FTId=VAR_012277.
FT   CONFLICT    527    527       Q -> E (in Ref. 7; AAH14036).
FT                                {ECO:0000305}.
FT   CONFLICT    756    756       G -> S (in Ref. 7; AAH14036).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1235 AA;  138408 MW;  6CA10CFFA86A582A CRC64;
     MRSRSNSGVR LDGYARLVQQ TILCYQNPVT GLLSASHEQK DAWVRDNIYS ILAVWGLGMA
     YRKNADRDED KAKAYELEQN VVKLMRGLLQ CMMRQVAKVE KFKHTQSTKD SLHAKYNTAT
     CGTVVGDDQW GHLQVDATSL FLLFLAQMTA SGLRIIFTLD EVAFIQNLVF YIEAAYKVAD
     YGMWERGDKT NQGIPELNAS SVGMAKAALE AIDELDLFGA HGGRKSVIHV LPDEVEHCQS
     ILFSMLPRAS TSKEIDAGLL SIISFPAFAV EDVNLVNVTK NEIISKLQGR YGCCRFLRDG
     YKTPREDPNR LHYDPAELKL FENIECEWPV FWTYFIIDGV FSGDAVQVQE YREALEGILI
     RGKNGIRLVP ELYAVPPNKV DEEYKNPHTV DRVPMGKVPH LWGQSLYILS SLLAEGFLAA
     GEIDPLNRRF STSVKPDVVV QVTVLAENNH IKDLLRKHGV NVQSIADIHP IQVQPGRILS
     HIYAKLGRNK NMNLSGRPYR HIGVLGTSKL YVIRNQIFTF TPQFTDQHHF YLALDNEMIV
     EMLRIELAYL CTCWRMTGRP TLTFPISRTM LTNDGSDIHS AVLSTIRKLE DGYFGGARVK
     LGNLSEFLTT SFYTYLTFLD PDCDEKLFDN ASEGTFSPDS DSDLVGYLED TCNQESQDEL
     DHYINHLLQS TSLRSYLPPL CKNTEDRHVF SAIHSTRDIL SVMAKAKGLE VPFVPMTLPT
     KVLSAHRKSL NLVDSPQPLL EKVPESDFQW PRDDHGDVDC EKLVEQLKDC SNLQDQADIL
     YILYVIKGPS WDTNLSGQHG VTVQNLLGEL YGKAGLNQEW GLIRYISGLL RKKVEVLAEA
     CTDLLSHQKQ LTVGLPPEPR EKIISAPLPP EELTKLIYEA SGQDISIAVL TQEIVVYLAM
     YVRAQPSLFV EMLRLRIGLI IQVMATELAR SLNCSGEEAS ESLMNLSPFD MKNLLHHILS
     GKEFGVERSV RPIHSSTSSP TISIHEVGHT GVTKTERSGI NRLRSEMKQM TRRFSADEQF
     FSVGQAASSS AHSSKSARSS TPSSPTGTSS SDSGGHHIGW GERQGQWLRR RRLDGAINRV
     PVGFYQRVWK ILQKCHGLSI DGYVLPSSTT REMTPHEIKF AVHVESVLNR VPQPEYRQLL
     VEAIMVLTLL SDTEMTSIGG IIHVDQIVQM ASQLFLQDQV SIGAMDTLEK DQATGICHFF
     YDSAPSGAYG TMTYLTRAVA SYLQELLPNS GCQMQ
//
